Stefan Bernstein explains how the EU/Greenland critical raw materials partnership benefits GreenRoc. Watch the full video here.
Hemogenyx Pharmaceuticals (HEMO), a biotech sector player with a market cap of $50.05 million,
( prior to todays trading )
The stock has exhibited a notable 53.65% upward movement compared to its sector peers over the last month.
Trading activity has surged with the last day's volume reaching 31,492,660 shares, which is significantly beyond the three-month average, marking a 279.9% increase.
Despite this, the company's price performance over the past week shows a decline of 10%. However, its year-to-date price change stands at a robust 46.74%.
The relative strength index (RSI) for HEMO is at 60.17. Recently, the company has seen a spike in news and social media attention within the last 24 hours.
Numbers -
Vol today - 22.6 million
Yesterday 32 million
Friday 129 million
Average 3 month vol -9 million
Very volatile & poor few sessions since RNS
always sceptical regarding market shenanigans especially after such a positive RNS ,
heavy volume , huge spread , delayed large trades , seller in chunks & random posters turn up , mmm …
Orchestrated if sceptical.
Hemo need to toss a CAR T partnership / pharma deal on an RNS backed by Prevail ,
That would certainly suffice & dwarf the recent shenanigans.
Afternoon all invested scratching their heads & balls in bewilderment….
3.1 p
After such a huge RNS Friday - Hemo are clinical on CAR T
Prevail - invested & underpinning through clinical at invested 100 % higher than current stock price .
& still cooking CBR & CDX
Hemo are doing brilliant science & making great steps as per Fridays RNS
Very content with my holding & lth ,
As I’ve noted before always sceptical on the market shenanigans & this sell off started at 5.5p on Friday & has continued until 3 p ,
Orchestrated , over last few weeks maybe , Fridays rise was the sell trigger sold into & continued
129 million vol Friday - 30 million yesterday -23 million today .
The whole steady gain for last month has been sold back .
Anyhow potential partnerships/ pharma deal on CAR T would certainly dwarf these shenanigans.
Leaving the CAR T Grog on the shelf today
May I add
Very Content with my holding & been here donkeys yrs so have a low average , & especially after Fridays RNS & previous RNS outlining Prevail , CBR , CDX
However market shenanigans always frustrating & makes your kippers curl .
Wouldn’t surprise me if the stock price reverses today & those sold ( whoever they maybe ) flip the trades .
Hemo are in a great position based on RNS just a volatile Rocky road
Grog stays in the cupboard for now
Morning all
Always a reason in my experience, 30 million traded & after such a positive RNS a trapdoor leathering
Certainly strange after such a positive RNS & underpinned by Prevail in CAR T clinical .
& Prevail invested at a premium of current 100%
orchestrated, if sceptical , markets will always make money in both directions.
Let’s see what develops ,
Always best to be Sceptical on the market shenanigans,
On Ortex today -
when you read this & Prevails RNS - you can’t believe todays market shenanigans to be honest & would drive any man to Grog for sure whilst scratching one’s balls .
Hemogenyx Pharma gets US FDA consent to proceed with phase I trials of HEMO-CAR-T to treat acute myeloid leukaemia
Information Solutions
Hemogenyx Pharmaceuticals plc, a pre-clinical stage biopharmaceutical group,
announced that it has been informed by the US Federal Food and Drug Administration (FDA) that it has lifted the clinical hold on the Investigational New Drug (IND) application for HEMO-CAR-T for the treatment of acute myeloid leukaemia (AML). The FDA confirmed that the company had addressed all issues identified in its prior clinical hold letter satisfactorily and consents to the company proceeding with its phase I clinical study of HEMO-CAR-T.
Dr Vladislav Sandler, chief executive officer, commented: “We are extremely pleased with the FDA’s decision to lift the clinical hold. We now look forward to accelerating clinical development of HEMO-CAR-T and to offering patients a potentially life-saving treatment. The removal of the clinical hold was made possible by the hard work and dedication of the entire Hemogenyx Pharmaceuticals team and its board of directors and advisors.”
AML, the most common type of acute leukaemia in adults, has poor survival rates (a five-year survival rate of less than 30% in adults) and is currently treated using chemotherapy, rather than the potentially more benign and effective form of therapy being developed by Hemogenyx Pharmaceuticals. The successful development of a new therapy for AML would have a major impact on treatment and survival rates for the disease.
CAR-T therapy is a treatment in which a patient’s own T-cells, a type of immune cell, are modified to recognize and kill the patient’s cancer cells. The procedure involves: isolating T-cells from the patient; modifying the isolated T-cells in a laboratory using a CAR gene construct (which allows the cells to recognize the patient’s cancer); amplifying (growing to large numbers) the newly modified cells; and re-introducing the cells back into the patient.
Hemogenyx Pharmaceuticals is a publicly traded company headquartered in London, with its US operating subsidiaries, Hemogenyx Pharmaceuticals LLC and Immugenyx LLC, located in New York City at its state-of-the-art research facility.
The company is a pre-clinical stage biopharmaceutical group developing new medicines and treatments to treat blood and autoimmune disease and to bring the curative power of bone marrow transplantation to a greater number of patients suffering from otherwise incurable life-threatening diseases.
The info is everywhere on Hemo , can someone let the markets know ! ..
Closing price 3.26 -
-14%
31 million vol
Vwap 3.58
Last minute delayed kippers
Date Time Trade Prc Volume Buy/Sell Bid Ask Value
12-Feb-24 15:41:18 3.41099 500,000 Unknown* 3.26 3.49 17.05k O
12-Feb-24 15:30:10 3.15 635,237 Unknown* 3.26 3.49 20.01k O
Not a great session & very sceptical on the shenanigans - let’s see if anything comes out in the wash
Still clinical in CAR T - with Prevail underpinning.
Two delayed kippers & look like sells at low of day the 1.3 million
12-Feb-24 13:49:48 3.251 1,305,227 Unknown* 3.30 3.50 42.43k O
12-Feb-24 14:49:46 3.45 500,000 Unknown* 3.30 3.50 17.25k O
Vwap 3.60
Volume 28 million
Certainly strange after such a positive RNS & underpinned by Prevail in CAR T clinical .
orchestrated, if sceptical .
Let’s see what develops ,
Afternoon
That was a volatile hour , with a hard push south in 20 million volume
Bounced off 3.35
Always a reason in my experience for a sudden drop / rise & didn’t expect to be mid 3s after Fridays RNS ,
Seller , buyer , placing , incoming RNS or just orchestrated by trading group , who knows
Seems to be moving back up now , which makes me even more sceptical with targeted market shenanigans.
Vwap 3.73
Let’s see what next few days bring
Hemo are clinical on CAR T - # frustrated .
Time for a. Bacon banjo & let Fridays news sink in to the markets
All invested await potential clinical partnerships / investment on CAR T
Let’s see what this week brings
Not forgetting- CDX & CBR
Fetch the bacon + sauce washed down with Grog
Evening all
Hold a small position here & have traded the crazy volatility in recent weeks for Rum cash , however looks a very decent LT hold/buy with recent drilling RNS etc ,
so will keep my eyes watching with a bag of dry powder .
A Few numbers for anyone interested
( source - Ortex )
In the industrial gases sector, Helium One Global Ltd has recently outpaced its counterparts, with a notable increase of 294.9% over its peers in the last month.
The stock's price performance over the past week has seen a 13.05% uptick, while its Year-To-Date price change stands at an impressive 587.5%
. Additionally, Relative Strength Index (RSI) is registered at 71.35.
Stock on loan / shorts
3 million - approx £70k value - down 15k
Cost to borrow - 52
Dtc - 5.6
No flagged shorts to report
MCap - 75 million
Heavy volume in recent sessions
52 week high 10p
52 week low - 0.2p
Good luck all invested here in these volatile markets , however it does bring out the good , the bad & the ugly .
Evening most
Decent graft go into that post Mont , thumbs up .
Precious metals in demand & wars are expensive but obviously not without risk .
Noted many times -
Green Energy boom / precious metal world demand Vs War situation/ economic climate
Worth holding stock at current price imo .so I will do .
Runs & wait for the ass nibblers all Round
Afternoon all invested
Looking forward to another week for Hemo investors , had a lubrication of grog & a belly full of Sunday grub & ready for market action .
Whatever the market shenanigans on Friday ,
Hemo is Clinical on CAR T & underpinned by Prevail & pharmas will imo be queuing up for partnerships / licensing deals like a Whitby chippy on bank holiday .
Some toxic knackers on here today after some very genuine & sincere posts yesterday, simply no need dudes , Hemo are now in a great position , absorb & Enjoy .
Fetch the CAR T deals & grog
Popped up on Ortex - last night plenty of publicity is good ( I appreciate it’s similar info but to a new investor audience )
Hemogenyx Pharmaceuticals PLC Announces FDA Consents to Phase I Trials of HEMO-CAR-T
Stock House
10th Feb 18:36
FDA Consents to Phase I Trials of HEMO-CAR-T LONDON, UK/ ACCESSWIRE/ February 9, 2024/ Hemogenyx Pharmaceuticals plc is pleased to announce that it has been informed by the U.S.
Federal Food and Drug Administration ("FDA") that it has lifted the clinical hold on the Investigational New Drug (IND) application for HEMO-CAR-T for the treatment of acute myeloid leukemia ("AML"). The FDA confirmed that the Company had addressed all issues identified in its prior clinical hold letter satisfactorily and consents to the Company proceeding with its Phase I clinical study of HEMO-CAR-T.
Dr Vladislav Sandler, CEO & Co-Founder of Hemogenyx Pharmaceuticals, commented: "We are extremely pleased with the FDA's decision to lift the clinical hold. We now look forward to accelerating clinical development of HEMO-CAR-T and to offering patients a potentially life-saving treatment. The removal of the clinical hold was made possible by the hard work and dedication of the entire Hemogenyx Pharmaceuticals team and its Board of Directors and advisors."
About AML and CAR-T Therapy
AML, the most common type of acute leukemia in adults, has poor survival rates (a five-year survival rate of less than 30% in adults) and is currently treated using chemotherapy, rather than the potentially more benign and effective form of therapy being developed by Hemogenyx Pharmaceuticals. The successful development of a new therapy for AML would have a major impact on treatment and survival rates for the disease.
CAR-T therapy is a treatment in which a patient's own T-cells, a type of immune cell, are modified to recognize and kill the patient's cancer cells. The procedure involves: isolating T-cells from the patient; modifying the isolated T-cells in a laboratory using a CAR gene construct (which allows the cells to recognize the patient's cancer); amplifying (growing to large numbers) the newly modified cells; and re-introducing the cells back into the patient.
Fetch the CAR T Clinical Grog